Migraines affect over 1 billion people around the world and can cause serious problems, often making it hard to do daily activities. Atogepant (Qulipta) is a newer medicine for migraines, while propranolol (Inderal) and topiramate (Topamax) have been used for many years. All three medicines are FDA approved to treat and prevent migraines. If you want to join the study, you will have an in-person visit to see if you qualify, and you will need to keep a headache diary for 4 weeks. At your next visit, you will be randomly placed, like flipping a coin, to take one of the three migraine medicines. The study will give you the medicine at no cost to you. You will fill out surveys about your health, medical history, migraines, and any symptoms of depression or anxiety. Then you will start taking the medicine you were assigned. You will know which medication you are getting. You will take the study medicine as a pill for 12 weeks. The whole study lasts 16 weeks, and you will have 5 visits during that time, which may be virtual or in-person. You will also need to keep an electronic daily headache. If after 16 weeks, your doctor wants you to keep taking the same medicine you took during the study, you will be able to continue taking it on your own. You can earn up to $550 if you finish all visits and complete your electronic headache diaries.

Who can Participate

You may be able to join this study if you are between 18 and 70 years old and have chronic migraines or migraines with or without aura. You also need to have at least 4 migraines each month that are moderate to severe. This means the migraine lasts at least four hours or you need to take a migraine-specific medication to feel better. You must not have ever taken atogepant (Qulipta), propranolol (Inderal), or topiramate (Topamax) to be able to join this study.

Study ID